Introduction: Nephropathy is a kidney complication that affects up to 50% of people with diabetes during their lifetime. Diabetes is the first cause of kidney failure. The aim of this study was to examine the relationship between diabetic nephropathy (DN) and arterial stiffness.
Methods: We conducted a prospective study including 249 diabetic patients without macroangipathic complications, between July 2020 and May 2021. Using a SphygmoCor®XCEL device, we measured arterial stiffness directly by the carotid to femoral pulse wave velocity (cfPWV).
Results: The mean age of the study population was 57.53 ± 9.34 years (139 women and 110 men). The mean duration of the disease was 10.2 years. Diabetic nephropathy (DN) was found in 34.5 % of the patients. The mean microalbuminuria was 48.58±86.67 mg/g of creatinuria. CfPWV > 10 m/s was found in 96.5 % of the patients with DN. And the mean microalbuminuria in patients with cfPWV > 10 m/s was 52.36±90.17 mg/g of creatinuria. In this group, cfPWV was at 14.38 ± 2.70 m/s VS 13.25 ± 2.81 m/s in patients without DN (P=0.002). We did not find a correlation between cfPWV and the stage of the nephropathy. Moreover, the presence of arterial stiffness multiples by 5 the risk of diabetic nephropathy (Odds Ratio =5).
Conclusion: This study shows that arterial stiffness is higher in type 2 diabetic patients with diabetic nephropathy than in those without diabetic nephropathy. Indeed, an elevated microalbuminuria is a marker of arterial stiffness in the general population and in the diabetic and hypertensive population. Several studies have investigated the relationship between arterial stiffness in type 2 diabetics, but there is little information regarding the relationship between cfPWV and microalbuminuria.
21 May 2022 - 24 May 2022